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Aim. Tumor angiogenesis in contrast to physiological one is characterized by high level of malignant cell
production of pro- angiogenic cytokines, which have different influence on functional activity of endothelial 
cells. The goal of the study – to carry out   a   comparative analysis of  the  influence of  a vascular endothelial 
growth factor (VEGF) and an  epidermal growth factor (EGF) on proliferative activity and survival of
endothelial cells   upon  their confluent and exponential growth. Methods. The proliferative activity of
endothelial cells was determined by MTT-test and their viability was detected by  the   trypane blue exclusion 
test. Results. It was shown that EGF (irrespectively of the level of serum factors) in concentrations higher
than 10 ng/ml activated the proliferative activity of confluent endotheliocytes in a concentration-dependent
manner by 18–36 %  (ð < 0.05) as compared to the control, while this cytokine didn’t affect the endothelial
cells in the exponential growth phase.  VEGF  in wide concentration range didn’t display the mitogenic
effect on endotheliocytes in both confluent and exponential  growth phases. Furthermore, VEGF in
concentrations higher than 100 ng/ml inhibited proliferative activity of confluent endothelial cells  by 12 %
(ð < 0.05).  In case of deficiency of nut- rients, EGF and VEGF promoted the survival of endothelial cells,
considerably decreasing their death. Conclusions. EGF, in con- trast to VEGF, stimulates proliferation
and survival of the endo- thelial cells, whereas VEGF has significant influence only on the survival of the
cells.
Keywords: epidermal growth factor (EGF), vascular endothelial growth factor, proliferative activity,
endothelial cells.
Introduction A number of current investigations have
proven the existence of two phases of angiogenesis.
The first phase includes activation of endotheliocytes,
increase in vascular permeability, degradation of basal
membrane, migration and invasion of endothelial cells
into extracellular matrix, active proliferation of
endotheliocytes and formation of “lumens”; the second 
phase is differentiation with the formation of
microvascular network [1–3].
The first phase of angiogenesis was simulated in
vitro by exponential growth of endotheliocytes and the
second one was mimicked by “stationary” (confluent)
growth [2, 4, 5].
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Proliferation, migration, and differentiation of
endothelial cells are mediated by many specific
pro-angiogenic cytokines. The determination of their
activity, the production of which by tumour cells under
neoangiogenesis is very high  contrary to that under
physiological angiogenesis, could offer tools to study
the mechanism of action of specific agents or to
pathways of therapeutic correction of their effect [4, 6,
7]. 
Taking the above mentioned into consideration, the 
aim of this research was to perform  a comparative
analysis of the influence of main pro-angiogenic
cytokines EGF and VEGF (decode) on proliferative
activity and viability of endothelial cells in the
confluent and exponential growth phase, as well as at 
the condition of deficiency of serum factors in growth
medium.
The tasks of investigation were as follows:
isolation and purification of native EGF and VEGF,
maintenance of exponential and confluent growth of
endothelial cells in vitro; determination of the
influence of cytokines on proliferative activity of
endotheliocytes in a wide range of concentrations;
comparison of the cytokines effect on proliferative
activity of endothelial cells depending on the time of
incubation with EGF and VEGF and in the absence of
serum in growth medium.
Materials and Methods VEGF (Sigma, USA),
goat polyclonal antibodies against VEGF (Sigma),
heparin-sepharose (Amersham, USA), polyclonal
rabbit anti-goat immunoglobulins labelled with horse
peroxidase (Dako Cytomation, USA), MTT
(tetrazolium blue) and trypane blue (Sigma) were used
in the work.
Cell lines and conditions of cultivation. MAEC
(endothelial cells from aorta of mice [8]) were
incubated in DMEM medium (Sigma) with addition of
10% fetal bovine serum (FBS) (Sigma) and at
non-serum conditions. The incubation time for
endothelial cells was 3–96 hours at 100% humidity,
t=37°C, and 5% CO2.
Purification of native EGF and VEGF. Native EGF 
from submandibular glands of non-linear male mice
was purified by the method, previously proposed by us, 
using mini-columns Sep-Pak C18  [9]. The EGF
preparation was of high purity (95% of total protein)
and attached to specific receptors on the cells of A-431
line (the data are not presented).
The cells of LLC/R9 subline were used as a
producent of  mouse VEGF as the data of
immuno-enzyme assay, performed  with the mouse
VEGF kit (R&D, England), testify to a high level of
producing this cytokine by the cells [10]. VEGF was
purified by two-stage chromatography considering the
basic physical and chemical features of cytokine,
namely, pI = 8.5 and high affinity to heparin [11].
After liophilisation the peptide was identified using 
Western-blot analysis with recombinant mouse VEGF   
(Sigma) and goat polyclonal anti-VEGF  antibodies
(Sigma) (Fig.1). As seen, the molecular mass of VEGF, 
purified by us, is identical to the recombinant VEGF
(Sigma). According to the protein  amount, calculated
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Fig.1 Western-blot analysis of native VEGF (1) (10 µg of total protein per one sample) and recombinant VEGF (10 µg per one sample) (2).
Detection was performed using goat anti-VEGF-antibodies (Sigma), visualization was conducted by anti-goat antibodies labelled with
horse peroxidase and the system of photo-sensitive reagents ECL (Amersham).
similarly to the recombinant VEGF (Fig.1), the amount 
of peptide, obtained by us, was 1 µg per 3.6 µg of total
protein in eluate. This index was considered  for 
calculating the concentration of native VEGF while
determining its biological activity.
The investigation of  influence of EGF and VEGF
on proliferative activity of endothelial cells.
Proliferative activity of endothelial cells was
determined by MTT-test [12] calculating the number of 
living cells per well ( units of 540 nm extinction  )  as
well as by routine calculation   of  the  cells in
hemocytometer using trypane blue. The data, obtained
by the first procedure, were presented in percents of the 
corresponding control taken as 100%. To study the
influence of cytokines on proliferative activity of
endothelial cells in “stationary” (confluent) and
exponential growth phases, the cell seeding densities
were experimentally determined. The previous data [7,
13] and results of experimental study show the
following optimal concentrations: 5x103 cells per well
of 96-well plate – in the exponential growth phase,
almost 4 days; 25x103 cells per well – in the confluent
growth phase (Fig.2). To analyse the mitogenic effect
of EGF and VEGF, they were used in a wide range of
concentrations added to the cells in the confluent
growth phase during two days of incubation. To
determine the influence of EGF and VEGF on the
viability of endothelial cells, they were studied in the
concentration of 10 ng/ml at the exponential growth in
a standard growth medium with 10% FBS and in
non-serum medium.
The results were statistically processed by
parametric and non-parametric methods using Origin
6.0 software package.
Results and Discussion The effect of EGF and
VEGF on proliferative activity of endothelial cells was
found to depend significantly on the growth phase. The
screening of mitogenic effect of EGF and VEGF on
endothelial cells in the confluent growth phase was
performed in a wide range of the factors concentration
(1–1000 ng/ml). After 24-hour incubation of cells with
cytokines EGF showed the mitogenic effect on
confluent cells at these concentrations. This effect was
also  proven by the increase in a number of living cells
per well by 17–35% (p<0.05) compared to the control
(Table 1). The increase in the mitogenic effect was
observed with the increase in EGF concentration. This
correlates with the data of other authors [14] who
proved that proliferative activity of endothelial cardiac
cells of rats at monolayer growth with 10% serum
increases by almost 1.5 times at the addition of EGF in
the concentration range of 0.1–100 ng/ml; the
maximum effect was observed at the cytokine
concentration of 5 ng/ml. No significant influence of
VEGF on proliferative activity of endotheliocytes in
the concentration range of 1.0–5.0 ng/ml was observed. 
An insignificant, but statistically valid decrease in the
number of endotheliocytes by 12% (p<0.05) at the
VEGF concentrations of 100.0–1,000.0 ng/ml was
revealed. It was not due to the cytotoxic influence of
cytokine, as the number of dead cells did not exceed
5–10% of their total number and did not differ
considerably from the control. Inconsiderable
inhibition of endotheliocytes proliferation (cytostatic
effect), caused by VEGF after 24 hours, may be
explained by the reverse regulation of the cells specific
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Fig.2 Growth kinetics of MAECs (6–96 hours) at conditions of their
seeding with initial density of 5x103 (a) and 25x103 cells per well
(b)
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receptors under the influence of high concentration of
definite cytokine. 
The prolongation of incubation with
pro-angiogenic cytokines up to two days caused an
increase of the EGF mitogenic effect on the cells in the
confluent growth phase. For instance, the 48-hour
influence of EGF in the concentration of 10 ng/ml
resulted in increasing amount of living cells per well by 
36.5±1.5% (p<0.05) compared to the respective control 
(Fig.3), while there was no registered stimulating effect 
of the corresponding VEGF concentration on
proliferation of endotheliocytes.
As for the growth of cells in exponential phase,
neither of growth factors showed stimulating or
inhibiting effect at incubation with cells in adequate
nutrient medium, containing 10% FBS (Fig.3, b).
There was also neither increase nor decrease in the
viability index of endothelial cells in exponential
growth phase under the influence of EGF and VEGF
(the data are not presented).
The investigation of the cytokine influence at
serum factors deficiency demonstrated that EGF and
VEGF had different effect on proliferative activity of
endotheliocytes (Fig.4, a, b). The data presented show
(Fig.4, a) that the influence of VEGF in the
concentration of 10 ng/ml on proliferative activity of
endothelial cells was insignificant at different cell
seeding density. Contrary to VEGF, the influence of
EGF results in the increase in endothelium proliferative 
activity: on the first day of incubation there was only a
tendency to the activation of cell proliferation at all cell 
seeding densities, while on the second day we revealed
190
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Range of cytokine
concentrations, ng/ml
EGF VEGF
Number of living cells,
 extinction units
Number of dead cells, 
% of total amount
Number of living cells,
 extinction units
Number of dead cells, 
% of total amount
0 1.01±0.04 7.9±0.3 1.01±0.04 7.9±0.3
1.0–5.0 1.1±0.1 6.4±1.0 0.98±0.05 6.3±1.3
10.0–50.0 1.18±0.08* 8.1±1.7 0.99±0.05 8.2±1.8
100.0–1000.0 1.32±0.07* 4.9±1.1 0.90±0.04* 7.3±1.5
N o t e. Valid difference (p>0.05) from respective control is marked in Tables 1–3 with an asterix.
Table 1
Influence of EGF and VEGF on proliferative activity and survival of endothelial cells in confluent growth phase (cell incubation time
with cytokines – 24 hours)
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Fig.3 Influence of EGF (1) and VEGF (2) (concentration 10 ng/ml) on proliferative activity of endothelial cells in their confluent (a) and
exponential (b) growth phases. Incubation of cells at   standard conditions with 10% FBS  during  0–48 hours.
at high cell concentrations ( 50x103 cells per well) a
valid increase in the number of living cells almost by
30% (p<0.05) (Fig.4, b).
It is noteworthy that in control experiments, i.e. cell 
incubation in non-serum nutrient medium without any
introduction of cytokines, there was demonstrated a
progressive increase in the percentage of dead cells
which was 36% on average by the end of the second
day (p<0.05) compared to 7% of dead cells at the initial
seeding.
Both EGF and VEGF cause significant decrease in
the percentage of dead cells by 70% (p<0.05) after two
days of incubation, thus promoting survival of
endothelial cells at deficiency of growth factors and
nutrients (Table 2, 3).
Therefore, the results obtained testify to the
mitogenic effect of EGF on endothelial cells in the
confluent growth phase in both adequate cultural
medium and non-serum medium, as well as to the valid
increase in the index of cell viability, caused by EGF.
On the contrary, VEGF does not show any mitogenic
effect in regards to endotheliocytes, though it is also the 
factor, promoting survival of cells.
Therefore, the results obtained by us on the effect
of EGF and VEGF on actively proliferating endothelial 
cells and endotheliocytes in the confluent growth phase 
evidence that the mentioned cytokines influence
different phases of angiogenesis.  Considering that
EGF in vitro demonstrates mitogenic effect on cells in
the confluent growth phase and at serum factor
deficiency, it may influence in vivo the involvement of
endothelial cells of blood vessels into tumour
angiogenesis and induce the proliferation of
endotheliocytes, while VEGF is a factor, stimulating
the formation of lumens and new vessels.
There are proofs that inhibition of the
EGF-receptor of endothelial cells in the confluent
growth phase results in lower VEGF secretion which is
the basis of inhibition of the endothelial cells
morphogenesis [15]. Hence, in our case the activation
of endothelial cells proliferation in monolayer under
the influence of EGF and triggering a signalling
cascade via EGF-receptor may also be partially
determined by higher secretion of the main
pro-angiogenic cytokine – VEGF. The fact that both
cytokines cause a decrease in the number of dead cells
at serum factors deficiency testifies to their capability
of promoting the endothelial cells survival which is in
good agreement with the published data [15, 16].
Recently there have been a large number of
investigations on the stimulation of proliferation of
endothelial cells by the growth factors [4, 14, 17] and
on the inhibition of proliferation of endothelial cells as
main targets of anti-tumour angiogenesis-mediated
therapy [6, 18, 19].
Conclusions This work has revealed that EGF
demonstrates the mitogenic effect on endothelial cells
in the confluent growth phase in both adequate cultural
medium and non-serum medium; however, EGF does
not influence the mitogenic activity of endotheliocytes
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Fig.4 Influence of VEGF (a) and EGF (b) in the concentration of 10 ng/ml on proliferative activity of endothelial cells at   their incubation in
non-serum medium. The cells were sown with different initial density (10 x103 (1), 25 x103 (2), 50 x103 (3) cells per well) and incubated with
cytokine for 4–48 hours.
in the exponential growth phase. Contrary to EGF, no
mitogenic activity of VEGF has been revealed. Both
cytokines promote the survival of endothelial cells
growing at serum factors deficiency.
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Ë. Â. Ãàð ìàí ÷óê, Î. Ì. Ïÿñ êî âñüêà, Ã. ². Ñî ëÿ íèê 
Âïëèâ ïðî àíã³îãåí íèõ öè òîê³í³â íà ïðîë³ôå ðà òèâ íó àê òèâí³ñòü 
òà âè æè âàí íÿ åí äî òåë³àëü íèõ êë³òèí
Ðå çþ ìå
Ïóõ ëèí íèé àíã³îãå íåç íà â³äì³íó â³ä ô³ç³îëîã³÷íî ãî õà ðàê òå ðè -
çóºòüñÿ âè ñî êèì ð³âíåì ïðî äó êó âàí íÿ ïóõ ëèí íè ìè êë³òè íà ìè
ïðî àíã³îãåí íèõ öè òîê³í³â, ÿê³ ïî-ð³çíî ìó ä³þòü íà
ôóíêö³îíàëü íó àê òèâí³ñòü åí äî òåë³àëü íèõ êë³òèí. Ìåòà ðî -
áî òè – ïðî âåñ òè ïîð³âíÿëü íèé àíàë³ç âïëè âó ôàê òî ðà ðîñ òó åí -
äî òåë³àëü íèõ êë³òèí (VEGF) òà åï³äåð ìàëü íî ãî ôàê òî ðà
ðîñ òó (EGF) íà ïðîë³ôå ðà òèâ íó àê òèâí³ñòü ³ âè æè âàí íÿ åí äî -
òåë³àëü íèõ êë³òèí çà ¿õíüî ãî åê ñïî íåíö³éíî ãî òà êîí ôëþ åí -
òíî ãî ðîñ òó. Ìå òî äè. Ïðîë³ôå ðà òèâ íó àê òèâí³ñòü ³
âè æè âàí íÿ åí äî òåë³àëü íèõ êë³òèí ë³í³¿ ÌÀÅÑ ï³ä âïëè âîì EGF 
òà VEGF âèç íà ÷à ëè çà ÌÒÒ-òåñ òîì ³ ï³äðà õóí êîì æè âèõ
êë³òèí ç âè êî ðèñ òàí íÿì òðè ïà íî âî ãî ñèíü î ãî. Ðå çóëü òà òè.
EGF (íå çà ëåæ íî â³ä ð³âíÿ ñè ðî âàò êî âèõ ôàê òîð³â) ó êîí öåíò-
ðàö³ÿõ, á³ëüøèõ çà 10 íã/ìë, àê òè âóº ïðîë³ôå ðà òèâ íó àê -
òèâí³ñòü åí äî òåë³îöèò³â çà óìîâ êîí ôëþ åí òíî ãî ðîñ òó  íà
18–36 %  (ð < 0,05) åôåê òèâí³øå ïîð³âíÿ íî ç êîí òðî ëåì, òîä³
ÿê ïðè åê ñïî íåíö³éíî ìó ðîñò³ åí äî òåë³îöèò³â ñóòòºâîãî âïëè -
âó çà çíà ÷å íî ãî öè òîê³íó íà ïðîë³ôå ðàö³þ êë³òèí íå âè ÿâ ëå íî.
VEGF ó øè ðî êî ìó ä³àïà çîí³ êîí öåí òðàö³é íå ïðî ÿâ ëÿº ì³òî ãåí -
íî ãî åôåê òó íà åí äî òåë³îöè òè  çà óìîâ ÿê êîí ôëþ åí òíî ãî, òàê 
³ åê ñïî íåíö³éíî ãî ðîñ òó. Á³ëüøå òîãî, ó êîí öåí òðàö³ÿõ, âè ùèõ
çà 100 íã/ìë, VEGF íà 12 % (ð < 0,05) ³íã³áóº ïðîë³ôå ðà òèâ íó
àê òèâí³ñòü åí äî òåë³àëü íèõ êë³òèí â óìî âàõ êîí ôëþ åí òíî ãî
ðîñ òó. Ó ðàç³ äåô³öèòó ñè ðî âàò êî âèõ ôàê òîð³â îá èä âà öè -
òîê³íè ñïðè ÿ þòü âè æè âàí íþ åí äî òåë³àëü íèõ êë³òèí, ñóòòºâî
çìåí øó þ ÷è ¿õíþ çà ãè áåëü. Âèñ íîâ êè. EGF íà â³äì³íó â³ä VEGF
ñòè ìó ëþº ÿê ïðîë³ôå ðàö³þ åí äî òåë³àëü íèõ êë³òèí, òàê ³ ¿õíº
âè æè âàí íÿ, òîä³ ÿê VEGF ñïðèÿº ëèøå  âè æè âàí íþ åí äî -
òåë³îöèò³â.
Êëþ ÷îâ³ ñëî âà: åï³äåð ìàëü íèé ôàê òîð ðîñ òó (EGF), ôàê -
òîð ðîñ òó åí äî òåë³àëü íèõ êë³òèí (VEGF), ïðîë³ôå ðà òèâ íà àê -
òèâí³ñòü,  åí äî òåë³àëüí³ êë³òèíè ç àîð òè ìè øåé ë³í³¿ ÌÀÅÑ.
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Incubation time,
hours
Initial density of cells, thousands per well
10.0 25.0 50.0
Control VEGF Control VEGF Control VEGF
4.0 4.16±0.4 – 11.4±1.1 – 5.66±1.52 –
24.0 20.6±10 18.5±3.75 10.7±5.8 8.64±1.9 15.4±0.25 3.8±1.5*
31.0 15.05±5.45 9.7±4.5 22.7±3.0 11.2±3.3 18.9±1.5 5.5±0.9*
48.0 47.15±9.9 14.7±3.5 31.2±3.6 10.2±3.4* 27.5±2.9 8.5±0.9*
Table 2
Influence of VEGF on survival of endotheliocytes (estimated by the number of dead cells per well in %  of total amount) at   their
incubation in non-serum medium
Incubation time,
hours
Initial density of cells, thousands per well
10.0 25.0 50.0
Control EGF Control EGF Control EGF
4.0 4.16±0.4 – 11.4±1.1 – 5.66±1.52 –
24.0 20.6±10 11.68±0.38 10.7±5.8 4.0±0.4 15.4±0.25 7.5±1.7*
31.0 15.05±5.45 8.4±0 22.7±3.0 5.4±2.3* 18.9±1.5 7.5±3.5*
48.0 47.15±9.9 7.7±0.8* 31.2±3.6 8.1±2.3* 27.5±2.9 7.7±1.9*
Table 3
Influence of EGF on survival of endotheliocytes (estimated by the number of dead cells per well in %  of  total amount) at   their
incubation in non-serum medium
Ë. Â. Ãàð ìàí ÷óê, Î. Í. Ïÿñ êî âñüêàÿ, Ã. È. Ñî ëÿ íèê
Âëè ÿ íèå ïðî àí ãè î ãåí íûõ öè òî êè íîâ íà ïðî ëè ôå ðà òèâ íóþ 
àê òèâ íîñòü è âû æè âà å ìîñòü ýí äî òå ëè àëü íûõ êëå òîê
Ðå çþ ìå
Îïó õî ëå âûé àí ãè î ãå íåç â îò ëè ÷èå îò ôè çè î ëî ãè ÷åñ êî ãî õà ðàê -
òå ðè çó åò ñÿ âû ñî êèì óðîâ íåì ïðî äó öè ðî âà íèÿ îïó õî ëå âû ìè
êëåò êà ìè ïðî àí ãè î ãåí íûõ öè òî êè íîâ, ïî-ðàç íî ìó âëè ÿ þ ùèõ íà 
ôóíê öè î íàëü íóþ àê òèâ íîñòü ýí äî òå ëè àëü íûõ êëå òîê. Öåëü
ðà áî òû – ïðî âåñ òè ñðàâ íè òåëü íûé àíà ëèç äå éñòâèÿ ôàê òî ðà
ðîñ òà ýí äî òå ëè àëü íûõ êëå òîê (VEGF) è ýïè äåð ìàëü íî ãî ôàê -
òî ðà ðîñ òà (EGF) íà ïðî ëè ôå ðà òèâ íóþ àê òèâ íîñòü è âû æè -
âà å ìîñòü ýí äî òå ëè àëü íûõ êëå òîê ïðè èõ êîí ôëþ ýí òíîì è
ýêñ ïî íåí öè àëü íîì ðîñ òå. Ìå òî äû. Ïðî ëè ôå ðà òèâ íóþ àê òèâ -
íîñòü è âû æè âà å ìîñòü ýí äî òå ëè àëü íûõ êëå òîê ëè íèè ÌÀÅÑ
ïðè âëè ÿ íèè EGF è VEGF îïðå äå ëÿ ëè  ÌÒÒ-òåñ òîì è ïîä ñ÷å -
òîì æè âûõ êëå òîê ñ èñ ïîëü çî âà íè åì òðè ïà íî âî ãî ñè íå ãî. Ðå -
çóëü òà òû. EGF (íå çà âè ñè ìî îò óðîâ íÿ ñû âî ðî òî÷ íûõ ôàê-
òî ðîâ) â êîí öåí òðà öè ÿõ âûøå 10 íã/ìë àê òè âè ðó åò ïðî ëè ôå ðà -
òèâ íóþ àê òèâ íîñòü íà êîí ôëþ ýí òíîé ñòà äèè ðîñ òà ýí äî òå -
ëè î öè òîâ íà 18–36 %  (ð < 0,05) ýô ôåê òèâ íåå ïî ñðàâ íå íèþ ñ
êîí òðî ëåì, òîã äà êàê ïðè ýêñ ïî íåí öè àëü íîì ðîñ òå ýí äî òå ëè î -
öè òîâ ñó ùåñ òâåí íî ãî âëè ÿ íèÿ ýòî ãî öè òî êè íà íà ïðî ëè ôå ðà -
öèþ êëå òîê çà ôèê ñè ðî âà íî íå áûëî. VEGF â øè ðî êîì äè-
àïà çî íå êîí öåí òðà öèé íå ïðî ÿâ ëÿ åò ìè òî ãåí íî ãî ýô ôåê òà íà
ýí äî òå ëè î öè òû ïðè èõ êîí ôëþ ýí òíîì è ýêñ ïî íåí öè àëü íîì
ðîñ òå. Áî ëåå òîãî, â êîí öåí òðà öè ÿõ âûøå  100 íã/ìë VEGF íà
12 % (ð < 0,05) èí ãè áè ðó åò ïðî ëè ôå ðà òèâ íóþ àê òèâ íîñòü ýí -
äî òå ëè àëü íûõ êëå òîê ïðè êîí ôëþ ýí òíîì ðîñ òå. Â ñëó ÷àå äå -
ôè öè òà ñû âî ðî òî÷ íûõ ôàê òî ðîâ îáà öè òî êè íà ñïî ñîáñò-
âóþò âû æè âà íèþ ýí äî òå ëè àëü íûõ êëå òîê, ñó ùåñ òâåí íî óìå-
íüøàÿ èõ ãè áåëü. Âû âî äû. EGF â îò ëè ÷èå îò VEGF ñòè ìó ëè ðó -
åò êàê ïðî ëè ôå ðà öèþ ýí äî òå ëè àëü íûõ êëå òîê, òàê è èõ âû æè -
âà å ìîñòü, òîã äà êàê VEGF  ñïî ñî áñòâó åò òîëü êî âû æè âà-
åìîñ òè ýí äî òå ëè î öè òîâ. 
Êëþ ÷å âûå ñëî âà: ýïè äåð ìàëü íûé ôàê òîð ðîñ òà (EGF), ôàê -
òîð ðîñ òà ýí äî òå ëè àëü íûõ êëå òîê (VEGF), ïðî ëè ôå ðà òèâ íàÿ
àê òèâ íîñòü, ýí äî òå ëè àëü íûå êëåò êè èç àîð òû ìûøè ëè íèè
ÌÀÅÑ.
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